High grade neuroendocrine tumors (G3 NET) and neuroendocrine carcinomas (NEC) are a rare disease entity for which there is a limited amount of prospective data available. It has also been relatively recent that a distinction has been made between G3 NET and NEC, further complicating the approach for management. Due to the overall lack of data in this space, much of the practice for treatment of these tumors is based on expect opinion. The North American Neuroendocrine Tumor Society (NANETS) is an organization composed of experts who specialize in the management of these tumors. In an effort to provide further guidance to the oncology community in regard to the management of these rare tumors, NANETS convened a panel of experts from medical oncology, surgery, interventional radiology, nuclear medicine, radiology, pathology and radiation oncology to address critical issues surrounding the management of G3 NET and NEC that would benefit from expert consensus opinion. Here we present the recommendations from this panel of neuroendocrine experts in regard to the management of high grade, extra-pulmonary neuroendocrine tumors (G3 NET) and neuroendocrine carcinomas (NEC).
You are looking at 1 - 1 of 1 items for
- Author: Thorvardur R Halfdanarson x
- Refine by Access: Open Access content only x